Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Novabridge Biosciences ADR (NBP)

Novabridge Biosciences ADR (NBP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 326,274
  • Shares Outstanding, K 115,291
  • Annual Sales, $ 0 K
  • Annual Income, $ -22,230 K
  • EBIT $ -40 M
  • EBITDA $ -39 M
  • 60-Month Beta 1.60
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.43

Options Overview Details

View History
  • Implied Volatility 509.63% (+255.03%)
  • Historical Volatility 82.82%
  • IV Percentile 76%
  • IV Rank 34.16%
  • IV High 1,254.89% on 02/13/26
  • IV Low 122.97% on 12/19/25
  • Expected Move (DTE 6) 0.77 (27.03%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 131
  • Volume Avg (30-Day) 227
  • Put/Call OI Ratio 0.05
  • Today's Open Interest 3,331
  • Open Int (30-Day) 2,712
  • Expected Range 2.07 to 3.60

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.09
  • Number of Estimates 2
  • High Estimate -0.07
  • Low Estimate -0.11
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.01%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.81 +0.71%
on 03/13/26
3.86 -26.68%
on 03/05/26
-0.38 (-11.84%)
since 02/13/26
3-Month
2.81 +0.71%
on 03/13/26
5.19 -45.47%
on 01/06/26
-1.16 (-29.07%)
since 12/12/25
52-Week
0.60 +375.63%
on 04/04/25
6.79 -58.32%
on 10/16/25
+1.99 (+237.07%)
since 03/13/25

Most Recent Stories

More News
NovaBridge and Visara Announce Positive Results from VIS-101 Phase 2a Wet AMD Study

VIS-101, purpose-designed to be best-in-class for retinal vascular diseases, is a tetravalent, dual VEGF-A X ANG-2 inhibitor Topline Phase 2a data show VIS-101 provides rapid, robust and durable treatment...

NBP : 2.83 (-3.74%)
NovaBridge to Host Business Update Call to Review Phase 2a Data for VIS-101 in Wet AMD on Monday, March 9, 2026

VIS-101, purpose-designed to be a best-in-class dual VEGF-A/ANG-2 inhibitor, has the potential to provide more effective and durable treatment than the current standard of care for patients with wet AMD,...

NBP : 2.83 (-3.74%)
NovaBridge to Present at the Leerink Partners 2026 Global Healthcare Conference

ROCKVILLE, Md., March 02, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovative...

NBP : 2.83 (-3.74%)
NovaBridge Appoints Biotech Leader, Emmett T. Cunningham, Jr, MD, PhD, MPH, as Vice Chairman of the Board to Further Accelerate Global Biotech Platform

Appointment is a positive endorsement of NovaBridge’s unique hub-and-spoke model and focus on creating shareholder value by accelerating the development of transformative medicines for patients around...

NBP : 2.83 (-3.74%)
NovaBridge Doses First Patient in Global, Randomized Phase 2 Study of Givastomig Combined with Immunochemotherapy in Patients with 1L Metastatic Gastric Cancer

Global, randomized Phase 2 study to evaluate the addition of givastomig, a CLDN18.2 x 4-1BB bispecific antibody (8 mg/kg and 12 mg/kg) to standard of care immunochemotherapy in patients with first line...

NBP : 2.83 (-3.74%)
NovaBridge Announces Open Market Purchases by Executive Chairman, Fu Wei

ROCKVILLE, Md., Jan. 20, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovative...

NBP : 2.83 (-3.74%)
The $537B Precision Pivot: Why Molecular Monitoring is the New Oncology Standard

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – The war on cancer is moving into a high-tech era of molecular-guided defense. The genomics in cancer care...

ONCY : 0.9840 (+2.34%)
PYXS : 1.5400 (+0.65%)
PSNL : 6.72 (+1.97%)
NBP : 2.83 (-3.74%)
TOI : 2.84 (+8.40%)
NovaBridge Presents Positive Givastomig Dose Expansion Data from the Phase 1b Combination Study in Patients with 1L Metastatic Gastric Cancer

Givastomig, a CLDN18.2 x 4-1BB bispecific antibody, continues to show robust efficacy when combined with nivolumab and chemotherapy (mFOLFOX6) in 1L HER2-negative, metastatic gastric cancer patients, with...

NBP : 2.83 (-3.74%)
NovaBridge to Ring the Nasdaq Opening Bell on Friday, January 2, 2026

NovaBridge Also Included in the Highly Regarded Nasdaq Biotech Index, Emphasizing its Position as an Industry Leader Opening the first trading session of the New Year marks an excellent beginning...

NBP : 2.83 (-3.74%)
NovaBridge Presents Positive Ragistomig Phase 1 Dose Expansion Data at ESMO-IO

Ragistomig is a 4-1BB X PD-L1 bispecific antibody, designed to treat patients with advanced or metastatic solid tumors, including those who have relapsed or are refractory to checkpoint inhibitors, a multi-billion...

NBP : 2.83 (-3.74%)

Business Summary

NovaBridge Biosciences is a biotechnology platform company committed to accelerating access to innovative medicines. NovaBridge Biosciences, formerly known as I-MAB, is based in ROCKVILLE, Md.

See More

Key Turning Points

3rd Resistance Point 3.19
2nd Resistance Point 3.11
1st Resistance Point 2.97
Last Price 2.83
1st Support Level 2.75
2nd Support Level 2.67
3rd Support Level 2.53

See More

52-Week High 6.79
Fibonacci 61.8% 4.42
Fibonacci 50% 3.69
Fibonacci 38.2% 2.96
Last Price 2.83
52-Week Low 0.60

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar